Close
Contact

Emerging drug modalities targeting HER2

HER-2 is overexpressed in 20% of breast cancers, and since breast cancer has the highest prevalence worldwide, finding drugs to target HER2 is of paramount importance. This report aims to shed light on the emerging HER2-targeting drug modalities and highlight some of the most interesting molecular designs associated with them.

In this report you will find:

  • HER-2 targeting drugs in preclinical and Phase I development including ADCs, bispecifics, CAR therapies and cancer vaccines.
  • The most fascinating HER2 drugs in development along with their efficacy and toxicity results
  • An overview of the overall HER2 drug landscape

Do you have a future market research project that you’d like to discuss with us?

Contact

Customer Care

Inside Intelligence

Address: 52 Grosvenor Gardens, London, SW1W 0AU.
Tel: +44 (0)20 3141 8700

Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.

Enabling growth is at the heart of what we do.

© Hanson Wade 2024. Hanson Wade Limited is registered in England & Wales, number 06752216. Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.